Cargando…
Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events – a retrospective cohort study
BACKGROUND: Due to potentially immune-escaping virus variants and waning immunity, a third SARS-CoV-2 vaccination dose is increasingly recommended. However, data in patients with cancer are limited. PATIENTS AND METHODS: We measured anti-SARS-CoV-2 spike protein antibody levels after the third vacci...
Autores principales: | Mair, Maximilian J., Berger, Julia M., Mitterer, Manfred, Gansterer, Margaretha, Bathke, Arne C., Trutschnig, Wolfgang, Berghoff, Anna S., Perkmann, Thomas, Haslacher, Helmuth, Lamm, Wolfgang W., Raderer, Markus, Tobudic, Selma, Fuereder, Thorsten, Buratti, Thomas, Fong, Dominic, Preusser, Matthias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818387/ https://www.ncbi.nlm.nih.gov/pubmed/35248840 http://dx.doi.org/10.1016/j.ejca.2022.01.019 |
Ejemplares similares
-
Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron
por: Mair, Maximilian J., et al.
Publicado: (2022) -
SARS-CoV-2 screening in cancer outpatients during the second wave of the COVID-19 pandemic: Conclusions for crisis response at a high-volume oncology center
por: Berger, Julia M., et al.
Publicado: (2021) -
Timely course of SARS-CoV-2 infections and vaccinations in patients with hemato-oncological diseases: analysis of a real-life cohort
por: Mair, M.J., et al.
Publicado: (2023) -
1692P SARS-CoV-2 RNA testing in cancer patients treated at a Department of Medical Oncology in Vienna, Austria
por: Berghoff, A.S., et al.
Publicado: (2020) -
SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic
por: Fuereder, Thorsten, et al.
Publicado: (2020)